
Actinogen Medical completes final patient visit in Alzheimer’s trial, results due in November
Actinogen Medical has completed the final patient visit in its pivotal XanaMIA Phase 2b/3 trial for Alzheimer’s disease, with top-line results expected in November. The trial uses the p-tau181 blood biomarker to select patients likely to have Alzheim...





